Vanguard Personalized Indexing Management LLC Purchases 26,573 Shares of Genmab A/S Sponsored ADR $GMAB

Vanguard Personalized Indexing Management LLC increased its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 50.4% during the third quarter, Holdings Channel reports. The fund owned 79,257 shares of the company’s stock after purchasing an additional 26,573 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Genmab A/S were worth $2,431,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of GMAB. Osaic Holdings Inc. boosted its stake in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares in the last quarter. CWM LLC raised its holdings in shares of Genmab A/S by 28.3% in the third quarter. CWM LLC now owns 2,306 shares of the company’s stock valued at $71,000 after buying an additional 509 shares during the last quarter. Captrust Financial Advisors raised its holdings in shares of Genmab A/S by 2.4% in the second quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock valued at $464,000 after buying an additional 526 shares during the last quarter. Grandfield & Dodd LLC lifted its position in Genmab A/S by 1.6% during the 3rd quarter. Grandfield & Dodd LLC now owns 39,133 shares of the company’s stock worth $1,200,000 after buying an additional 630 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Genmab A/S by 6.2% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 13,468 shares of the company’s stock worth $440,000 after acquiring an additional 783 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GMAB. Truist Financial reaffirmed a “buy” rating and issued a $48.00 target price (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $39.00 target price on shares of Genmab A/S in a research report on Wednesday. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.25.

Key Stories Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 price target on GMAB, implying roughly mid-teens upside from current levels — supportive of investor demand. H.C. Wainwright Reiterates Buy Rating on Genmab AS (GMAB)
• Positive Sentiment: HC Wainwright raised its FY2025 EPS projection to $2.00 (from $1.89), signaling higher expected full-year profitability that can support valuation. HC Wainwright / Marketbeat
• Neutral Sentiment: Genmab granted 32,806 restricted stock units and 34,307 warrants to employees. The award is standard compensation-related dilution but is very small relative to the company’s outstanding shares, so impact is likely minimal. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short-interest data for January appear anomalous (showing 0 shares / NaN change) and are inconclusive — not a reliable signal of bearish pressure at this time.
• Negative Sentiment: HC Wainwright cut near-term quarterly EPS forecasts (Q1 → $0.27 from $0.34; Q2 → $0.49 from $0.58; Q3 → $0.47 from $0.59), which reduces near-term earnings expectations and could weigh on sentiment if investors focus on short-term performance. HC Wainwright / Marketbeat

Genmab A/S Stock Performance

GMAB opened at $33.35 on Friday. The company has a fifty day moving average price of $32.42 and a two-hundred day moving average price of $28.97. The firm has a market capitalization of $21.42 billion, a PE ratio of 14.19, a P/E/G ratio of 18.54 and a beta of 0.90. Genmab A/S Sponsored ADR has a 52 week low of $17.24 and a 52 week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.17. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $975.40 million. Equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.